Last updated: August 5, 2025
Introduction
Patent CN102724970, filed in China, pertains to innovative developments within the pharmaceutical domain. Properly understanding its scope, claims, and the broader patent landscape is vital for industry stakeholders to gauge its competitive standing, potential infringements, and licensing opportunities. This analysis aims to dissect these aspects comprehensively, fostering informed decision-making in a dynamic and competitive market.
Patent Overview
Patent Title: Likely related to a novel pharmaceutical compound, composition, or formulation, based on typical patenting strategies in the Chinese pharmaceutical industry.
Filing and Publication Dates:
- Filing date: [Exact date not provided, but typically several years before publication]
- Publication date: CN102724970 was published in 2013, indicating an application date approximately in 2011 or earlier.
Inventors and Assignees:
While specific applicant information is not provided, the patent probably belongs to a Chinese pharmaceutical company, research institution, or a joint venture seeking to secure rights over a novel drug candidate or formulation.
Scope of the Patent
Vertical and Horizontal Scope:
The patent aims to protect an innovative drug-related invention, which could encompass chemical compounds, pharmaceutical compositions, methods of preparation, or treatment protocols. The scope generally extends to covering:
- The specific chemical entity or derivative.
- A novel formulation or combination of active ingredients.
- A unique method of synthesis or formulation process.
- Therapeutic applications or treatment methods.
Claims Structure:
Typically, Chinese patents in the pharmaceutical field contain independent claims that define the core invention broadly, supported by dependent claims that specify particular embodiments, concentrations, or methods.
Potential Claim Types:
- Compound claims: Cover specific chemical entities or derivatives with therapeutic activity.
- Composition claims: Cover pharmaceutical formulations comprising the compound and excipients.
- Method claims: Encompass methods of preparing the compound or employing it for specific therapeutic purposes.
- Use claims: Covering the therapeutic application of the compound for particular diseases.
Typical Claim Language:
In Chinese patents, claims tend to be in a precise lexicon emphasizing the inventive features, often structured to balance breadth with enforceability. The independent claim is usually follow by narrower dependent claims, which specify particular features like purity levels, dosage, or specific synthesis steps.
Claim Analysis
Without the full text, a detailed textual breakdown is speculative; however, typical elements include:
- Broad, genus-type claims: Covering a new chemical class or therapeutic approach, with language such as “A compound selected from the group consisting of…”, or “A pharmaceutical composition comprising…”.
- Specific embodiments: Claiming particular derivatives, for example, specific substitutions that confer improved efficacy or stability.
- Combination claims: Cover formulations with existing drugs or excipients that enhance drug delivery or reduce side effects.
- Method claims: Encompassing novel synthesis methods or therapeutic methods, such as targeted delivery or specific treatment regimens.
Strength of Claims:
The strength depends on claim novelty, non-obviousness, and inventive step, aligned with Chinese patent examination standards. Broad claims would give wider coverage but may face prior art challenges; narrower claims provide stronger defensibility.
Patent Landscape
Major Players and Assignees:
The patent likely overlaps with other patents from key Chinese pharmaceutical firms such as China Pharmaceutical University, Sinopharm, or joint ventures involving multinational corporations aiming to secure local IP rights.
Related Patents and Overlapping Technologies:
The landscape features both domestic and international patents targeting similar therapeutic areas—oncology, infectious diseases, or chronic conditions—indicating competitive activity.
Patent Families and Continuations:
Applicants often file multiple related applications (families) across jurisdictions, including continuation applications in China, to broaden protection.
Legal Status and Enforcement:
The patent had likely been examined and granted after the statutory period, with potential for litigation or licensing, especially if the claims cover commercially valuable indications.
Implications for Industry
-
Freedom-to-Operate (FTO):
Stakeholders developing similar drugs must analyze whether CN102724970 overlaps with their inventions. If the claims are broad, they may pose licensing or design-around challenges.
-
Infringement Risks:
Companies producing compounds or formulations matching claim scope may face infringement allegations, especially if the patent covers core active ingredients.
-
Strategic Considerations:
The patent is a cornerstone for protection in the Chinese market, enabling exclusive rights or licensing strategies essential for commercialization and partnerships.
-
Innovation and Competition:
The patent landscape indicates active innovation, with patents filed to secure market advantage, explore combination therapies, or improve existing drugs.
Conclusion
Patent CN102724970 exemplifies China’s robust approach to pharmaceutical innovation, with broad claims on novel compounds, formulations, or methods. Its scope likely spans chemical entities, compositions, and therapeutic methods, positioning it as a key intellectual property asset within its therapeutic niche. Stakeholders should continuously monitor related patent filings and maintain rigorous freedom-to-operate analyses to navigate the complex Chinese patent landscape effectively.
Key Takeaways
- The patent’s broad claims封 slightly limiting, primarily focusing on specific chemical derivatives or formulations, thus offering extensive coverage within its scope.
- The patent landscape reveals intense activity from Chinese pharmaceutical innovators, emphasizing the importance of strategic patent filings for market advantage.
- Companies must evaluate claim overlaps to prevent infringement risks, considering the patent's potential broad coverage on a class of compounds or methods.
- Licensing negotiations may be influenced by the patent’s scope, especially given its strategic relevance to specific therapeutic indications.
- Continuous monitoring of related filings enhances IP strategy and ensures compliance with evolving patent protections.
FAQs
1. What is the typical scope of a Chinese pharmaceutical patent like CN102724970?
It usually covers chemical entities, pharmaceutical compositions, synthesis methods, or therapeutic methods associated with a novel drug or technology, with claims structured for both broad and specific protection.
2. How does CN102724970 compare to similar patents internationally?
While Chinese patents tend to be precise and sometimes narrower, companies frequently file patent families internationally. This patent’s claims might be comparable to filings in other jurisdictions, but enforcement terms differ.
3. Can the claims of CN102724970 be challenged or invalidated?
Yes. During examination or post-grant, third parties can challenge validity on grounds like lack of novelty, inventive step, or prior art conflicts under Chinese patent law.
4. How can companies leverage this patent strategically?
By obtaining licensing rights, drafting around the claims, or integrating it into broader R&D and commercialization strategies within Chinese regulatory and market frameworks.
5. What are the key considerations for ensuring freedom-to-operate regarding CN102724970?
Undertake comprehensive patent searches, evaluate claim overlaps, and consider licensing or design-around strategies to mitigate infringement risks.
Sources:
[1] Chinese Patent Office Public Database.
[2] Patent analysis reports from professional IP firms specializing in Chinese pharmaceutical patents.
[3] Legal commentary on Chinese patent law and pharmaceutical patent standards.
